Abstract
As part of the 37th Annual European Association of Urology (EAU) Congress, this symposium presented key data from the CLEAR study: a Phase III randomised controlled trial evaluating lenvatinib plus pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma (RCC) in the first-line (1L) setting.1 Leading experts discussed strategies for optimising treatment outcomes in RCC using lenvatinib plus pembrolizumab and considered how to identify the right patients for this combination therapy in clinical practice.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call